1. Which of the following activating mutations is NOT associated with a response to targeted therapy (e.g. tyrosine kinase inhibitors)?

2. As part of the manifestation of paraneoplastic syndromes, ADH is most commonly associated with what lung carcinoma subtype?

3. Gain of function mutations (e.g. tyrosine kinase mutations) in lung cancer are most commonly associated with which of the following subtypes:

4. Adenocarcinoma in situ of the lung should not have evidence of invasion, and should be less than:

5. Which of the following is least helpful in differentiating between a typical and atypical carcinoid?

6. Approximately what percentage of cases of newly diagnosed lung cancer occur in heavy smokers (or those who recently quit)?